Meropenem
- Generic Name
- Meropenem
- Brand Names
- Vabomere
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O5S
- CAS Number
- 96036-03-2
- Unique Ingredient Identifier
- YOP6PX0BAO
- Background
Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
...
- Indication
For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, vi...
- Associated Conditions
- Bacterial Infections, Complicated Intra-Abdominal Infections (cIAIs), Meningitis, Bacterial, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin infection bacterial
- Associated Therapies
- -
Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Antabio
- Target Recruit Count
- 48
- Registration Number
- NCT06527677
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Beneficência Portuguesa de São Paulo
- Target Recruit Count
- 176
- Registration Number
- NCT06342115
- Locations
- 🇧🇷
A Beneficência Portuguesa de São Paulo, São Paulo, Brazil
Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis
- Conditions
- Interventions
- First Posted Date
- 2023-12-28
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Scandinavian Critical Care Trials Group
- Target Recruit Count
- 5800
- Registration Number
- NCT06184659
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, København Ø, Denmark
Cefepime-taniborbactam Vs Meropenem in Adults with VABP or Ventilated HABP
- Conditions
- Interventions
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 316
- Registration Number
- NCT06168734
Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- King Abdul Aziz Specialist Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06072248
- Locations
- 🇸🇦
King abd el Aziz specialist hospital, Ta'if, Saudi Arabia
Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- King Abdul Aziz Specialist Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06072222
- Locations
- 🇸🇦
King abd el Aziz specialist hospital, Ta'if, Saudi Arabia
Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
- Conditions
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 734
- Registration Number
- NCT05922124
FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Antabio
- Target Recruit Count
- 72
- Registration Number
- NCT05905913
- Locations
- 🇫🇷
Biotrial, Rennes, France
Antimicrobial Revision in Persistent Febrile Neutropenia
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT05784844
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit
- Conditions
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 600
- Registration Number
- NCT05565222
- Locations
- 🇫🇷
MAYAUX Julien, Paris, France
🇫🇷LUYT Charles -Edouard, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.